NASDAQ · ALGS
Healthcare · Biotechnology
$5.38
Down-$0.02 (-0.37%)
Updated Oct 7, 2026, 9:53 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALGS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ALGS closed at $5.38 after 21 trading sessions, down 6.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $5.46 | $5.53 | $5.3103 | $5.38 | 12.84K |
| Oct 5, 2026 | $5.57 | $5.65 | $5.35 | $5.40 | 48.61K |
| Oct 2, 2026 | $5.58 | $5.72 | $5.37 | $5.54 | 29.04K |
| Oct 1, 2026 | $5.69 | $5.74 | $5.3668 | $5.50 | 28.26K |
| Sep 30, 2026 | $5.65 | $5.80 | $5.54 | $5.63 | 35.33K |
| Sep 29, 2026 | $5.53 | $5.68 | $5.40 | $5.62 | 11.49K |
| Sep 28, 2026 | $5.38 | $5.54 | $5.18 | $5.54 | 79.52K |
| Sep 25, 2026 | $5.70 | $5.765 | $5.47 | $5.51 | 45.05K |
| Sep 24, 2026 | $5.55 | $5.695 | $5.27 | $5.55 | 59.87K |
| Sep 23, 2026 | $5.72 | $5.9356 | $5.45 | $5.56 | 35.07K |
| Sep 22, 2026 | $5.57 | $6.30 | $5.2221 | $5.68 | 75.69K |
| Sep 21, 2026 | $5.31 | $5.88 | $5.21 | $5.49 | 125.05K |
| Sep 18, 2026 | $5.15 | $5.25 | $5.015 | $5.24 | 21.34K |
| Sep 17, 2026 | $5.10 | $5.29 | $5.10 | $5.17 | 21.71K |
| Sep 16, 2026 | $5.01 | $5.13 | $4.93 | $5.05 | 41.65K |
| Sep 15, 2026 | $5.04 | $5.445 | $4.82 | $4.99 | 34.49K |
| Sep 14, 2026 | $5.17 | $5.27 | $5.02 | $5.04 | 28.02K |
| Sep 11, 2026 | $5.39 | $5.5019 | $5.14 | $5.22 | 37.04K |
| Sep 10, 2026 | $5.38 | $5.48 | $5.21 | $5.33 | 46.07K |
| Sep 9, 2026 | $5.79 | $6.02 | $5.4101 | $5.50 | 33.02K |
| Sep 8, 2026 | $6.21 | $6.3396 | $5.62 | $5.76 | 64.24K |
The latest Smart Investors Daily articles mentioning ALGS.
Company
Market Activity
Research & News
ALGS research
Company profile and research snapshot.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 28, 2026 | Lake Street | Buy | — |
| May 21, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 26, 2026 | WestPark Capital | Buy | — |
| Mar 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 7, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 21, 2026
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Yahoo · Sep 2, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above
Yahoo · Sep 2, 2026
Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.
Benzinga · Aug 12, 2026
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALGS.
